No Data
ARS Pharmaceuticals Is Maintained at Outperform by Leerink Partners
ARS Pharmaceuticals Analyst Ratings
Express News | Corrected-ARS Pharmaceuticals Q4 Neffy Product Revenue of USD 6.5 Million (Corrects to Clarify Amount Is Not for Co's 'revenue', and Removes Reference to Estimate)
ARS Pharmaceuticals Lays Down 2025 Objectives for Epinephrine Nasal Spray
ARS Pharmaceuticals Highlights Success and Plans for 2025
ARS Pharma Announces Preliminary Q4 2024 Results With Neffy Revenue At $6.5M; 14.5K Units Delivered. Cash Reserves At $314M To Fund Operations For 3 Years; 2025 Strategy Includes Expanding Neffy Access, Increasing Awareness, And Seeking FDA Approval...